Association of p53 Overexpression with       Hormone Receptor Status and Triple Negative Breast Carcinoma

Qamar, Samina; Khokhar, Muhammad Abbas; Farooq, Shahid; Ashraf, Sobia; Humayon, Waqar A; Rehman, Abdul

doi:10.29271/jcpsp.2019.02.164

Cited by 9 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study showed a correlation between HER2 overexpression and tumor grade with a significant p-value similar to Charfi et al [5]. In the present study, the expression of p53 in various grades of urothelial carcinomas was analyzed and it demonstrated a significant association with high tumor grade, which is consistent with the study by Qamar et al [14]. With the above results and observations, this study intended to evaluate the expression of p53, p63, and HER2 in urothelial carcinoma and analyze its association with tumor grade.…”

Section: Discussionsupporting

confidence: 92%

Correlation of HER2 With p53 and p63 in Urothelial Bladder Carcinoma

Ponnaboina¹,

Perumandal²,

Sreelakshmi³

2023

Cureus

View full text Add to dashboard Cite

Urothelial carcinomas account for the majority of all primary bladder cancers, making bladder cancer the second most frequent genitourinary malignancy after prostate cancer. Bladder cancer risk rises with age and most of them return after resection due to their multifocal distribution, and they often develop in superficial locations. Like many other cancers, bladder carcinoma is associated with a few tumor markers that have been evaluated in the past. They include p53, p63, and HER2. This study was conducted on 88 patients suspected of urinary bladder carcinoma. This prospective study was done at the Department of Pathology, Osmania General Hospital, Hyderabad from August 2017 to July 2019. Of the 88 patients, 76 were diagnosed with bladder carcinoma and the remaining 12 were non-neoplastic. The primary neoplastic lesions of the urinary bladder were predominantly seen in patients older than 40 years and were found to be statistically significant (p<0.01). Of the 34 cases of high-grade papillary urothelial carcinoma (PUC), 26 (76.47%) were males, eight cases (23.53%) were females, while among the 25 cases of low-grade PUC, 20 cases (80%) were males, and five cases (20%) were females. In seven cases of squamous cell carcinoma, six cases (85.71%) were males and only one case (14.29%) was female. Of the two cases of adenocarcinoma, male and female gender accounted for one case each (50%). The two cases of papillary urothelial neoplasm of low malignant potential were males in the study. On the whole, the primary urinary bladder lesions are more predominant in the males (77.63%) than the females (22.37%). Overexpression of p53 is negatively connected to p63 expression, and HER2 and p53 were strongly associated with high tumor grade in urothelial carcinoma.

show abstract

Section: Discussionsupporting

confidence: 92%

Correlation of HER2 With p53 and p63 in Urothelial Bladder Carcinoma

Ponnaboina¹,

Perumandal²,

Sreelakshmi³

2023

Cureus

View full text Add to dashboard Cite

show abstract

“…Somatic mutations in the TP53 gene occur in almost every type of cancer at rates up to 50% and are more frequent in advanced stage or in cancer subtypes with aggressive behavior (23). In particular, the TP53 gene was found to be mutated in approximately 80% of TNBC, and high levels of p53 in TNBC have been associated with poor prognosis (24).…”

Section: Introductionmentioning

confidence: 99%

Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer

Wilson

Sultana

Shah

et al. 2021

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Doxorubicin and other anthracycline derivatives are frequently used as part of the adjuvant chemotherapy regimen for triple-negative breast cancer (TNBC). Although effective, doxorubicin is known for its off-target and toxic side effect profile, particularly with respect to the myocardium, often resulting in left ventricular (LV) dysfunction and congestive heart failure when used at cumulative doses exceeding 400 mg/m2. Previously, we have observed that the ribonucleotide reductase subunit M2 (RRM2) is significantly overexpressed in estrogen receptor (ER)–negative cells as compared with ER-positive breast cancer cells. Here, we inhibited RRM2 in ER-negative breast cancer cells as a target for therapy in this difficult-to-treat population. We observed that through the use of didox, a ribonucleotide reductase inhibitor, the reduction in RRM2 was accompanied by reduced NF-κB activity in vitro. When didox was used in combination with doxorubicin, we observed significant downregulation of NF-κB proteins accompanied by reduced TNBC cell proliferation. As well, we observed that protein levels of mutant p53 were significantly reduced by didox or combination therapy in vitro. Xenograft studies showed that combination therapy was found to be synergistic in vivo, resulting in a significantly reduced tumor volume as compared with doxorubicin monotherapy. In addition, the use of didox was also found to ameliorate the toxic myocardial effects of doxorubicin in vivo as measured by heart mass, LV diameter, and serum troponin T levels. The data present a novel and promising approach for the treatment of TNBC that merits further clinical evaluation in humans.

show abstract

“…Overexpression of the receptor may overcome the blockage of the receptor and result in the cell becoming sensitive to hormonal stimulation. Such tendencies are mostly observed in prostate and breast cancers ( 37 – 39 ). The latter is connected with the expression of estrogen receptor which is a predictive and prognostic marker in hormone-dependent cancers.…”

Section: Introductionmentioning

confidence: 95%

Chemotherapy and Physical Therapeutics Modulate Antigens on Cancer Cells

et al. 2022

View full text Add to dashboard Cite

Cancer cells possess specific properties, such as multidrug resistance or unlimited proliferation potential, due to the presence of specific proteins on their cell membranes. The release of proliferation-related proteins from the membrane can evoke a loss of adaptive ability in cancer cells and thus enhance the effects of anticancer therapy. The upregulation of cancer-specific membrane antigens results in a better outcome of immunotherapy. Moreover, cytotoxic T-cells may also become more effective when stimulated ex-vivo toward the anticancer response. Therefore, the modulation of membrane proteins may serve as an interesting attempt in anticancer therapy. The presence of membrane antigens relies on various physical factors such as temperature, exposure to radiation, or drugs. Therefore, changing the tumor microenvironment conditions may lead to cancer cells becoming sensitized to subsequent therapy. This paper focuses on the therapeutic approaches modulating membrane antigens and enzymes in anticancer therapy. It aims to analyze the possible methods for modulating the antigens, such as pharmacological treatment, electric field treatment, photodynamic reaction, treatment with magnetic field or X-ray radiation. Besides, an overview of the effects of chemotherapy and immunotherapy on the immunophenotype of cancer cells is presented. Finally, the authors review the clinical trials that involved the modulation of cell immunophenotype in anticancer therapy.

show abstract

Association of p53 Overexpression with Hormone Receptor Status and Triple Negative Breast Carcinoma

Abstract: A total of 91 patients were included with the help of non-probability purposive sampling.All female patients were over 18 years, diagnosed with breast cancer having reports of receptor status confirmed

Cited by 9 publications

References 22 publications

Correlation of HER2 With p53 and p63 in Urothelial Bladder Carcinoma

Correlation of HER2 With p53 and p63 in Urothelial Bladder Carcinoma

Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer

Chemotherapy and Physical Therapeutics Modulate Antigens on Cancer Cells

Contact Info

Product

Resources

About